CN Patent

CN101439182A — 一种生长抑素受体介导的肿瘤靶向药物组合物

Assigned to Peking University · Expires 2009-05-27 · 17y expired

What this patent protects

本发明涉及一种生长抑素受体介导的肿瘤靶向药物组合物，采用靶向生长抑素受体的功能多肽和聚乙二醇同时修饰药用载体，将抗肿瘤药物或/和抗血管药物输送到肿瘤部位，增强肿瘤治疗效果。

USPTO Abstract

本发明涉及一种生长抑素受体介导的肿瘤靶向药物组合物，采用靶向生长抑素受体的功能多肽和聚乙二醇同时修饰药用载体，将抗肿瘤药物或/和抗血管药物输送到肿瘤部位，增强肿瘤治疗效果。

Drugs covered by this patent

setmelanotide-acetate (SETMELANOTIDE ACETATE)

Patent Metadata

Patent number: CN101439182A
Jurisdiction: CN
Classification: —
Expires: 2009-05-27
Drug substance claim: No
Drug product claim: No
Assignee: Peking University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.